The Expression And Clinical Significance Of CD4~+CD25~+Foxp3~+Regulatory T Cells In Esophageal Cancer Patients

Background and objectives:CD4+CD25+regulatory T cell (Treg) is a class of T-cell subsets with the function of immune negative-phase regulation not only important in autoimmune diseases, transplant rejection and tumor immunity but also closely related with occurrence, development, treatment and prognosis of tumor. The immune suppression of CD4+CD25+Treg has an important meaning in maintaining body immune tolerance. The cut of CD4+CD25+Treg's number and (or) functions will cause relative hyperactivity of immune function due to immune suppression and triggered autoimmune disease. On the contrary, the increase will be conductive to immune escape of tumor. It was reported that compared with normal people, CD4+CD25+Treg in patients peripheral blood in non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, hepatocellular carcinoma, gastric cancer, B-cell non-Hodgkin's lymphoma, gliomas and other cancers are significantly increased. Cancer is a serious threat to human s health and safety. China is one of the countries for high incidence and high mortality of esophageal. Esophageal occurs in the elderly, and it was reported that 80% patients of our countries age of onset of 50 years. Currently there are surgery, chemotherapy, radiation therapy, microwave therapy, immunotherapy and so on. The 5-year survival rate of early post-operative patients with esophageal carcinoma is greater than 90%, but is only about 30% for post-operative patients with advanced esophageal cancer. Because of underlying diseases, middle-aged patients have poor tolerance to traditional therapies such as surgery and radiotherapy. Chemotherapy remains to be one of clinical treatments of esophageal and there is the need to seek new development of tumor immunity. CD4+CD25+Treg is one of the hot studies of tumor immunity. In this study, CD4+CD25+Treg of esophageal patients peripheral blood are detected by flow cytometry in order to study further about the relationship between CD4+CD25+Treg and clinical stage and chemotherapy for esophageal and its clinical significance to provide a basis for further development of clinical treatment.Methodsthe CD4+CD25+Foxp3+regulatory T cells of peripheral blood of 45 cases of esophageal cancer patients in our hospital and 15 normal volunteers were detected and correlation with clinical data analysis By flow cytometry. SPSS16.0 statistical software was used for data analysis of variance single factor, and the results of each group.ResultsThe average percentage of CD4+CD25+Treg cells of Esophageal cancer patients is (11.24±2.31)%,and healthy control group is (2.62±1.28)%. The average percentage of CD4+CD25+Treg cells in esophageal cancer patients of different stages is that the result betweenⅠandⅢ,ⅠandⅣ,ⅡandⅣare statistically significant(P<0.05),and the result ofⅢandⅣis higher than I and II, and the difference is statistically significant(P<0.01). The CD4+CD25+Treg cells'ratio of esophageal cancer patients of different pathological types is:squamous cell carcinoma (11.26±3.53)%, adenocarcinoma (10.72±2.90)%. The average ratio Before chemotherapy is (10.47±1.16)%, and after chemotherapy is (10.54±1.47)%. PR patients before chemotherapy:(10.83±2.14)%, after chemotherapy:(8.72±1.46)%. (SD+PD) patients:chemotherapy before:(11.35±2.52)%, after chemotherapy:(12.83±2.46)%.ConclusionThe CD4+CD25+Treg in CD4+T cells of esophageal cancer patients accounts for higher than normal. The ratio of different pathological types of esophageal cancer is not significantly different. The ratio is related to the clinical staging of esophageal cancer and CD4+CD25+Treg accounts for higher with the the stage. The ratio of PR patients after chemotherapy is lower than before chemotherapy, and the ratio of (SD+PD) after chemotherapy is significantly higher than that before chemotherapy, and the latter was significantly higher than the former.